KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Biomarin Pharmaceutical (BMRN) Other Gross PP&E Adjustments (2016 - 2025)

Biomarin Pharmaceutical's Other Gross PP&E Adjustments history spans 16 years, with the latest figure at $2.0 billion for Q4 2025.

  • For the quarter ending Q4 2025, Other Gross PP&E Adjustments rose 5.29% year-over-year to $2.0 billion, compared with a TTM value of $2.0 billion through Dec 2025, up 5.29%, and an annual FY2025 reading of $2.0 billion, up 5.29% over the prior year.
  • Other Gross PP&E Adjustments for Q4 2025 was $2.0 billion at Biomarin Pharmaceutical, roughly flat from $2.0 billion in the prior quarter.
  • The five-year high for Other Gross PP&E Adjustments was $2.0 billion in Q3 2025, with the low at $1.7 billion in Q1 2021.
  • Average Other Gross PP&E Adjustments over 5 years is $1.9 billion, with a median of $1.9 billion recorded in 2023.
  • Year-over-year, Other Gross PP&E Adjustments grew 9.59% in 2021 and then decreased 0.39% in 2025.
  • Tracing BMRN's Other Gross PP&E Adjustments over 5 years: stood at $1.7 billion in 2021, then rose by 5.55% to $1.8 billion in 2022, then rose by 5.03% to $1.9 billion in 2023, then increased by 0.32% to $1.9 billion in 2024, then grew by 5.29% to $2.0 billion in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Other Gross PP&E Adjustments are $2.0 billion (Q4 2025), $2.0 billion (Q3 2025), and $2.0 billion (Q2 2025).